Swisse Beauty Collagen Glow Gummies - Recall due to potential mould
Therapeutic Goods Administration (TGA)
Australian Government Department of Health
Main menu
- Home
- Safety information
- Report a problem or side effect
- Alerts
- Recalls
- Prescription opioids
- Medicine shortages
- Early warning system
- Black Triangle Scheme
- Safety information & education
- COVID-19
- COVID-19 vaccines
- COVID-19 vaccine approval process
- COVID-19 vaccines undergoing evaluation
- Provisional registrations
- COVID-19 vaccine safety monitoring and reporting
- News and updates
- COVID-19 vaccine advertising and import compliance
- Information for consumers and health professionals
- Information for sponsors (industry)
- International collaboration
- International COVID-19 vaccines recognised by Australia
- COVID-19 treatments
- COVID-19 treatments: Provisional determinations
- COVID-19 treatments: Provisional registrations
- COVID-19 treatments: Treatments undergoing evaluation
- COVID-19 treatments: Advertising compliance
- COVID-19 treatments: Information for consumers and health professionals
- COVID-19 treatments: Information for sponsors (industry)
- COVID-19 tests
- How testing works for COVID-19
- COVID-19 point-of-care tests
- COVID-19 rapid antigen self-tests
- COVID-19 rapid antigen tests - information for manufacturers and sponsors
- COVID-19 testing in Australia - information for health professionals
- Advertising COVID-19 rapid antigen point-of-care tests and self-tests (home use tests)
- Post market review of COVID-19 point-of-care tests
- Consumers
- Health professionals
- Accessing unapproved products
- Medicines
- Medical devices
- Breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)
- Changes to labelling and regulation of hard surface disinfectants (commencing 1 April 2019)
- Information for medical practitioners on pending up-classification of surgical mesh devices
- Patient information material for implantable medical devices
- Importing & supplying medical devices
- Advice about medical devices for health professionals
- Biologicals
- Other resources
- Health professional information & education
- Medicines Safety Update
- Administer vinca alkaloids by intravenous infusion only
- Clindamycin capsules and injections - acute kidney injury
- Clonidine - importance of dosing compliance and safe storage
- Direct acting oral anticoagulants and risk of recurrent thrombotic events
- Erenumab and hypertension
- Fluoroquinolone antibiotics and risk of aortic aneurysm/dissection
- Medicines Safety Update Volume 9 Number 3, August-September 2018
- Medicines Safety Update, Volume 9, Number 2, June 2018
- Medicines Safety Update, Volume 9, Number 4, December 2018
- Minocycline and agranulocytosis
- Propylthiouracil and carbimazole – use in pregnancy
- SGLT2 inhibitors approved for T2DM only
- Update - fluoroquinolone antibiotics and adverse events
- Industry
- SME Assist
- Regulation basics
- How therapeutic goods are regulated in Australia
- Australian Register of Therapeutic Goods
- Industry educational materials
- Legislation & legislative instruments
- Advertising hub
- Labelling & packaging
- Ingredients in therapeutic goods
- Exporting therapeutic goods
- Importing therapeutic goods
- Clinical trials
- Cosmetics
- International scientific guidelines
- Safety information for industry
- Medicine shortages
- Review of real world evidence and patient reported outcomes
- Advertising therapeutic goods
- Getting started
- Complying with advertising requirements
- Learning resources
- Enforcement and outcomes
- News and reports
- Consultation and independent reviews
- Advertising Code FAQs
- Guidance on applying the Advertising Code rules
- Obtaining approved COVID-19 rapid antigen tests
- The Therapeutic Goods Advertising Code
- Therapeutic Goods Advertising Code: Comparing the 2018 and 2021 Codes
- Prescription medicines
- Over-the-counter medicines
- Complementary medicines
- Sunscreens
- Medical devices & IVDs
- Australian conformity assessment bodies
- Conformity assessment certificates, changes to requirements for certain medical devices
- Consent for Non-compliant Medical Device(s) - Frequently Asked Questions
- Determinations for Australian conformity assessment bodies
- Face masks and COVID-19
- Medical devices regulation basics
- Overview of medical devices and IVD regulation
- Unique Device Identification system
- IVD medical devices regulation basics
- Standards, guidelines and publications
- Forms for medical device & IVD sponsors
- Medical devices reforms
- Regulatory decisions and notices
- Biologicals
- Blood and blood components
- Advanced therapies
- Other therapeutic goods
- Manufacturing therapeutic goods
- Manufacturing basics
- Manufacturing medicines
- Manufacturing medical devices & IVDs
- Manufacturing biologicals
- Manufacturing blood and blood components
- Manufacturing inspections
- Forms for manufacturers
- Notices for manufacturers
- Notices about GMP clearance
- Guidance on the management of GMP compliance signals
- Scheduling of medicines & poisons
- About the TGA
- News room
For information on accessing rapid antigen tests and what to do if you test positive, go to COVID-19 testing on the Department of Health website.
